DGAP-News: STRATEC to supply bioMérieux with components for the new VIDAS(R)
(firmenpresse) - STRATEC Biomedical Systems AG / Contract
15.06.2010 17:37
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
STRATEC to supply bioMérieux with components for the new VIDAS(R) automated
immunoanalyzer
Birkenfeld, June 15, 2010
STRATEC Biomedical Systems AG, Birkenfeld, Germany, (Frankfurt: SBS; Prime
Standard) and bioMérieux (NYSE Euronext: BIM) have signed a contract for
the development and supply of components for the next generation VIDAS(R)
instrument for in vitro diagnostics.
STRATEC will be responsible for the design and delivery of customized state
of the art modules for the new generation of VIDAS(R), which will offer the
same extensive clinical panel of 91 assays as the current system, including
infectious diseases, cardiovascular diseases and cancer for both routine
and high value medical testing. The new automated immunoanalyzer is
expected to be launched in 2012 in Europe and Asia-Pacific and in the US
after 2012.
The installed base of bioMérieux's VIDAS(R) is the largest of any
laboratory immunoassay platform, with around 26,000 systems operating
globally for clinical and industrial applications. With a workload of up to
100 tests per day, VIDAS(R) offers an economical solution for small to
medium sized laboratories and hospitals with a requirement for a user
friendly, automated analyzer which delivers results within minutes. These
features have also contributed to growing demand for the system in emerging
countries such as China.
Hermann Leistner, CEO of STRATEC commented: 'We are very pleased to have
gained the trust of bioMérieux to develop and deliver crucial components of
a new system, the predecessor of which is one of the most used and trusted
automated immunoanalyzer systems in the IVD industry worldwide. STRATEC is
delighted to contribute its expertise to make the new VIDAS(R) product line
an even greater success. With a launch in 2012 the new project will be an
additional contributor to STRATEC's growth in the medium term, giving us
additional confidence beyond our 2010 to 2012 revenue CAGR growth
projection of greater than 15%.'
About bioMérieux
Advancing Diagnostics to Improve Public Health - A world leader in the
field of in vitro diagnostics for over 45 years, bioMérieux is present in
more than 150 countries through 39 subsidiaries and a large network of
distributors. In 2009, revenues reached Euro 1.223 billion with 85% of
sales outside of France.
bioMérieux provides diagnostic solutions (reagents, instruments, software)
which determine the source of disease and contamination to improve patient
health and ensure consumer safety. Its products are used for diagnosing
infectious diseases and providing high medical value results for cancer
screening and monitoring and cardiovascular emergencies. They are also used
for detecting microorganisms in agri-food, pharmaceutical and cosmetic
products.
bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM - ISIN:
FR0010096479). Other information can be found at www.biomerieux.com.
About STRATEC
STRATEC Biomedical Systems AG (www.stratec-biomedical.de) designs and
manufactures fully automated systems for its partners in the fields of
clinical diagnostics and biotechnology. These partners market such systems,
in general together with their own reagents, to laboratories, blood banks
and research institutes around the world. The company develops its products
on the basis of its own patented technologies. Shares in the company (ISIN:
DE0007289001) are traded in the Prime Standard segment of the Frankfurt
Stock Exchange.
The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical Systems AG and of subsidiaries and second-tier subsidiaries in
Germany, the USA, the UK, Switzerland and Romania.
Further information can be obtained from:
STRATEC Biomedical Systems AG
AndréLoy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916 190
Fax: +49 7082 7916 999
E-mail: ir(at)stratec-biomedical.de
15.06.2010 17:37 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv atwww.dgap-medientreff.deandwww.dgap.de---------------------------------------------------------------------------
Language: English
Company: STRATEC Biomedical Systems AG
Gewerbestraße 37
75217 Birkenfeld
Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info(at)stratec-biomedical.de
Internet: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in München, Düsseldorf, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
Bereitgestellt von Benutzer: EquityStory
" alt="Formation Metals Finalizes Agreement for Powerline Right of Way on Idaho Cobalt ProjectDatum: 15.06.2010 - 17:37 Uhr
Sprache: Deutsch
News-ID 22473
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 315 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: STRATEC to supply bioMérieux with components for the new VIDAS(R)"
steht unter der journalistisch-redaktionellen Verantwortung von
STRATEC Biomedical Systems AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
